Echosens Underscores Impact of Obesity in Nonalcoholic Fatty Liver Disease & Metabolic Syndrome, Emphasizes Role of FibroScan to Monitor Liver Stiffness and Fat at Point-of-Care

Download: “Early Detection, Healthy Diet and Lifestyle Changes Critical for Addressing Metabolic Syndrome and Halting Progression of Liver Disease.”

WALTHAM, Mass.--(BUSINESS WIRE)-- Echosens, a high-technology company offering the FibroScan family of products, today announces the release of its white paper, “Early Detection, Healthy Diet and Lifestyle Changes Critical for Addressing Metabolic Syndrome and Halting Progression of Liver Disease,” authored by Dr. Juan Pablo Frias, M.D., medical director and principal investigator, National Research Institute, Los Angeles. This information-intensive paper highlights the link between obesity, metabolic syndrome and liver disease and stresses the importance of diet and lifestyle changes for preventing disease onset and progression.

“Growing prevalence of obesity is fueling increased rates of metabolic syndrome (MetS), and it may soon become the main risk factor for cardiovascular disease, ahead of cigarette smoking,” says Frias. “A weight loss program combined with FibroScan, a non-invasive examination for the diagnosis and monitoring of adult patients as part of an overall evaluation of liver health, is an effective approach for monitoring the impact of lifestyle changes on liver fat. FibroScan is likely to become a routine component of patient management.”

Studies show that nonalcoholic fatty liver disease (NAFLD)—the accumulation of lipids in liver cells not associated with the consumption of alcohol—is strongly associated with the features of MetS and that insulin resistance is a key pathogenic factor for both NAFLD and MetS.

Jon Gingrich, CEO, Echosens North America, states, “Industry leaders recognize the value of non-invasive diagnostic exams at the point-of-care to cost effectively gain quick insight into liver health to quantitatively estimate liver stiffness and fat content. FibroScan results provide critical information that enables heath care professionals to make the most informed treatment decisions, while also ruling out the need for an invasive and expensive liver biopsy or other invasive testing.”

About Echosens

Echosens, the developer of FibroScan^®, is an innovative high-technology company offering a full range of products and services supporting physicians in their assessment and management of patients with chronic liver diseases. FibroScan is supported by over 2,500 peer-reviewed publications and examinations are covered by Medicare, Medicaid and many insurance plans. For more information, please visit https://www.echosens.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005176/en/